Recent Updates
Recently added Catalysts

SC262

Phase 1

Non Hodgkin's Lymphoma | Small molecule | Oncology |Sana Biotechnology, Inc.|Last Updated: Nov 28, 2025

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLEDDMC
Total Trials1
Total Enrollment6
FDA Designations
No designations recorded
Clinical trial landscape

SC262 · 1 trial · 2 indications

Phase 1 1
NCT06285422Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)Non Hodgkin's Lymphoma
ACTIVE NOT_RECRUITING6 Analytics
PHASE1ACTIVE NOT_RECRUITING
Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID)
Non Hodgkin's Lymphoma
NCT062854226
Unlock trial analytics
Study Endpoints
Primary Endpoints
Evaluate safety and tolerability of SC262
24 months

Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities

Secondary Endpoints
Evaluate preliminary anti-tumor activity of SC262
24 months
Evaluate cellular kinetics and persistence of SC262
24 months
Evaluate host immunogenicity to SC262
24 months
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
SC262 Plus Chemotherapy RegimenEXPERIMENTALA conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC262
Interventions
NameTypeDescription
SC262DRUGSC262 is an allogeneic CAR -T cell therapy
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: 1. Male or Female Subject aged 18-80 years at the time of signing the informed consent 2. Histologic diagnosis of NHL (based on World Health Organization 2016 criteria) including: * LBCL, including Diffuse Large B Cell Lymphoma (DLBCL) not otherwise specified (NOS) (includin...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06285422primaryCompletionDate: changed
LOWMay 24, 2026NCT06285422studyFirstPostDate: changed